Global Coronavirus Cases Surge Past 1M, Medical Equipment Remains In Shortage

The number of novel coronavirus (COVID-19) cases globally surged past 1 million late Thursday, according to data from Johns Hopkins University.

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.

New COVID-19 Cases Rise Daily

At least 53,160 people have been confirmed dead around the world, and 211,775 have recovered.

The United States remains the worst-affected country at 245,559 cases, more than twice than that of the second worst-hit country Italy. Six thousand and fifty-seven deaths have been confirmed in the country.

The number of new cases being reported daily continues to rise, with 30,000 being reported on Thursday alone, signaling that the pandemic hasn’t yet peaked out globally.

Governments across the globe are also continuing to impose citizen lockdowns for all non-essential services as a protective measure against the further spread of COVID-19 in their countries.

Medical Protective Gear Remains In Shortage

Healthcare workers continue to suffer from a shortage of protective gears. In the United States, President Donald Trump utilized the Defense Production Act on Thursday to take control over the operations of private companies, including veteran N95 mask maker 3M Co. MMM. The measure is supposed to help make more protective gear available in the country.

According to the New York Times, the Center for Disease Control and Prevention is considering to recommend Americans wear “cloth masks” in public, and leave surgical and N95 masks for healthcare workers, who face increased risk from the virus due to continued exposure.

White House Coronavirus Task Force lead member Anthony Fauci has suggested that the development of Moderna Inc.’s MRNA COVID-19 vaccine is “on track” and can be expected in 12 to 18 months.

Other companies, including Johnson & Johnson JNJ and Inovio Pharmaceuticals Inc. INO, are also working on developing their own vaccine.

The authorities are relying on containment measures at the moment, but some experts have suggested that a drug to treat COVID-19 could become available earlier than the vaccine.

A number of companies including automakers Tesla Inc. TSLA, the Ford Motor Company F, and the General Electric Company GE have stepped in to produce medical equipment.

Posted In: ChinacoronavirusitalyThe New York TimesGovernmentNewsHealth CareMediaGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.